The franchising program is offered by MergersUK Limited, a UK Company with its registered office at 71-75 Shelton Street, Covent Garden, London, WC2H 9JQ, United Kingdom.
MergersCorp M&A International provides strategic business advisory services, including preparing companies for growth and capital access. Through partnerships with licensed investment bankers, clients can access tailored capital-raising solutions.
U.S. Investment Banking Securities transactions are exclusively conducted by Spektrum Capital Advisors LLC, a Registered Representative of, and Securities Products offered through, BA Securities, LLC, a FINRA-registered broker-dealer. Check the background of investment professionals associated with this site on Broker Check.
A leading provider of healthcare communication and interpretation services, delivering HIPAA- compliant, technology-enabled solutions to hospitals, health systems, and managed care organizations across the U.S.
The Company provid ...
Unique opportunity to acquire a rapidly scaling, fully remote telemedicine and digital prescription, GDPR-compliant platform operating under the EU cross-border framework. The business connects over 20,000 patients with licensed d ...
Find a Full List of Business for Sale, Health Care Businesses for sale, Buy Sell Side, Mergers & Acquisitions, Established Businesses for Sale at MergersCorp M&A International
A leading provider of healthcare communication and interpretation services, delivering HIPAA- compliant, technology-enabled solutions to hospitals, health systems, and managed care organizations across the U.S.
The Company provides medical video remote interpreting (VRI), telephonic interpretation, document translation, and on-site interpretation services, supported by a workforce of 550+ professionals and delivering more than 3.5 million interpretation minutes per month.
Founded 2019. 550+ workforce delivering 3.5M+ monthly interpretation minutes. 95%+ healthcare revenue concentration with long-term contracted clients.
Key Investment Highlights
$10.3M revenue in 2025, with $11.5M+ projected revenue for 2026
$2.3M EBITDA in 2025, representing a 22% EBITDA margin
95%+ of revenue generated from healthcare clients
Long-term relationships with hospitals, health systems, and managed care organizations
HIPAA and SOC II Type II certified infrastructure
Capital-light and scalable operating model
550+ workforce and 3.5M+ monthly interpretation minutes
Strong organic growth achieved without acquisitions
Growth Opportunities
The Company has significant potential for further expansion through health system and payer relationships, telehealth partnerships, geographic expansion, new service verticals, AI integration, and M&A.
Transaction Opportunity
The shareholders are considering a majority recapitalization, strategic partnership, or full acquisition to support the Company’s next stage of growth. Additional information is available to qualified parties following execution of an NDA.
DISCLAIMER
The information contained in this listing is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any security or business entity. Access to detailed financial data, target identification, and the Confidential Information Memorandum (CIM) is strictly contingent upon the prior execution of:
A Non-Disclosure Agreement (NDA) to protect the target company’s proprietary and sensitive business information.
A Buy-Side Fee Agreement governing the advisor/intermediary compensation structure upon the successful closing of a transaction.
No confidential or identifying information will be released prior to the full execution of both agreements by an authorized representative of the buyer.
